I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

Rhea-AI Summary

I-Mab, a clinical-stage biopharmaceutical company (Nasdaq: IMAB), will announce its full-year 2021 financial results on March 29, 2022, before the market opens. A conference call will follow at 8:00 a.m. EST to discuss the results and provide corporate updates. I-Mab focuses on developing novel biologics for immuno-oncology and autoimmune diseases, with over 20 clinical and preclinical drug candidates. The company aims to transition into a fully integrated global biopharmaceutical entity, enhancing its R&D and manufacturing capabilities.

Positive

• I-Mab has over 20 clinical and preclinical drug candidates, indicating a strong pipeline.
• The company is transitioning towards becoming a fully integrated global biopharmaceutical company, enhancing R&D and manufacturing capabilities.

Negative

• None.

SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2021 before the market opens on Tuesday, March 29, 2022, and host a conference call to discuss the results and provide a corporate update at 8:00 a.m. EST.

I-Mab Conference Call Information

Investors and analysts are invited to join the conference call at 8:00 a.m. EST on March 29 via Zoom:

Link:             https://i-mabbiopharma.zoom.us/j/91551271577?pwd=dzVRTENUdFlJVTFHNGV5eGExTTZydz09

Meeting ID:  915 5127 1577

Password:    953415

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development, and commercialization of novel and highly differentiated biologics for immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing, based on the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The Company is progressing from a clinical-stage biotech company into a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter , and WeChat.

I-Mab Contacts

John Long Chief Financial Officer IR@i-mabbiopharma.com

Gigi Feng Chief Communications Officer PR@i-mabbiopharma.com

Investor Inquiries

The Piacente Group, Inc. Emilie Wu E-mail: emilie@thepiacentegroup.com Office line: +86 21 6039 8363

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-report-full-year-2021-financial-results-and-provide-corporate-update-on-march-29-2022-301505716.html

SOURCE I-Mab

FAQ

When will I-Mab report its financial results for 2021?

I-Mab will report its financial results for the full year ended December 31, 2021, on March 29, 2022.

What is the schedule for I-Mab's conference call?

The conference call to discuss the financial results will take place at 8:00 a.m. EST on March 29, 2022.

What is the stock symbol for I-Mab?

I-Mab is traded on Nasdaq under the symbol IMAB.

What are I-Mab's main focuses as a biopharmaceutical company?

I-Mab is focused on the discovery, development, and commercialization of novel biologics for immuno-oncology and autoimmune diseases.